Advertisement

Topics

Teva Takes A Further Hit On Value Of Actavis

01:35 EDT 17 May 2019 | SCRIP

Teva has registered a further impairment of almost $500m, largely linked to the value of assets acquired when it took...

      

Related Stories

 

Original Article: Teva Takes A Further Hit On Value Of Actavis

NEXT ARTICLE

More From BioPortfolio on "Teva Takes A Further Hit On Value Of Actavis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...